CCR4-351

Cat. No.: HY-131349

CAS No.: 2174938-70-4

Molecular Formula: $C_{24}H_{27}Cl_2N_7O$

Molecular Weight: 500.42

Target: CCR

Pathway: GPCR/G Protein; Immunology/Inflammation

Storage: 4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 190 mg/mL (379.68 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.9983 mL	9.9916 mL	19.9832 mL
	5 mM	0.3997 mL	1.9983 mL	3.9966 mL
	10 mM	0.1998 mL	0.9992 mL	1.9983 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

CCR4-351 is an orally active, potent and selective CCR4 antagonist. CCR4-351, featuring a novel piperidinyl-azetidine motif, has IC_{50}s of 22 nM and 50 nM in the calcium flux and CTX assay. CCR4-351 has antitumor activity[1].

IC_{50} & Target

CCR4

In Vitro

CCR4-351 (compound 38) shows no activity in a CYP450 induction assay[1].

CCR4-351 inhibits the migration of mouse iT_{reg} cells with an IC_{50} of 39 nM, while the IC_{50} in human iT_{reg} cells is 33 nM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CCR4-351 (compound 38; 50 mg/kg; PO; daily; for 40 days) significantly reduces the tumor growth[1].

CCR4-351 (0.5 mg/kg; IV) has low clearance (CL=10.2 mL/min/kg), medium volume of distribution (V_{ss}=5.2 L/kg), a $T_{1/2}$ of 6.9 h, and good bioavailability (%F = 29) of oral dosing in mouse[1].

CCR4-351 has low clearance (CL=7.3 mL/min/kg), a half-life of 12.7 hr, and is 44% bioavailable in dog. CCR4-351 has low clearance (CL=3.7 mL/min/kg), a long terminal half-life (10.7 hr), and good bioavailability (%F = 41) in cynomolgus monkey[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-to eight-week-old, female C57BL/6 mice with Pan02-OVA tumor[1]
Dosage:	50 mg/kg
Administration:	PO; daily; for 40 days
Result:	Significantly reduced the tumor growth.

Animal Model:	Rat and mouse[1]
Dosage:	0.5 mg/kg of IV; 2 mg/kg of PO
Administration:	IV or PO
Result:	Possessed medium clearance (CL=47.6 mL/min/kg) and was 49% bioavailable upon oral dosing in rat. Had low clearance (CL=10.2 mL/min/kg), medium volume of distribution (V_{ss}=5.2 L/kg), a $T_{1/2}$ of 6.9 h, and good bioavailability (%F = 29) of oral dosing in mouse.

REFERENCES

[1]. Omar Robles, et al. Novel Piperidinyl-Azetidines as Potent and Selective CCR4 Antagonists Elicit Antitumor Response as Single Agent and in Combination with Checkpoint Inhibitors. J Med Chem. 2020 Jul 15.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA